z-logo
Premium
Validated LC–MS/MS method for quantitation of total and free mycophenolic acid concentration and its application to a pharmacokinetic study in pediatric renal transplant recipients
Author(s) -
Liu Yan,
Liu Longshan,
Li Jingjie,
Fu Qian,
Zhang Huanxi,
Wu Chenglin,
Li Jun,
Zhong Guoping,
Zheng Yifan,
Chen Xiao,
Wang Changxi,
Chen Pan
Publication year - 2021
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.4989
Subject(s) - chemistry , chromatography , free fraction , formic acid , pharmacokinetics , triple quadrupole mass spectrometer , mycophenolic acid , electrospray ionization , selected reaction monitoring , therapeutic drug monitoring , mass spectrometry , transplantation , pharmacology , tandem mass spectrometry , surgery , medicine , biochemistry , plasma protein binding
A simple and sensitive LC–MS/MS method was established to quantify total and free mycophenolic acid (MPA) plasma concentrations during immunosuppressive medication for pediatric renal transplantation. The chromatographic separation was performed with the Hypersil GOLD C 18 column, using a mobile phase consisting of 0.1% formic acid in water and acetonitrile (60:40, v/v) at an isocratic flow rate of 0.4 ml/min. An Agilent 6420 triple quadrupole mass spectrometer was operated via a positive electrospray ionization interface using the transitions m / z 321.14 → 206.9 for MPA and m / z 324.15 → 209.9 for MPA‐d3 (internal standard). The linearity was 0.1–50 μg/ml for total MPA and 0.0025–0.5 μg/ml for free MPA. The within‐run and between‐run precisions were all <5% and accuracy was within 96.23–107.63%. The validated method was successfully aspplied to a pharmacokinetic study in 28 pediatric renal recipients. The mean free fraction of MPA in our patients was 0.89% (ranging from 0.62 to 1.25%) and albumin level played a major role in the variability of free fraction of MPA, thus, in pediatric patients with hypoproteinemia, close free drug monitoring and dose adjustments should be considered to prevent toxicity.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here